Memantine Vipharm

Memantine, the active ingredient in Memantine Vipharm, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat cognitive symptoms of Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Vipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Memantine is indicated for the treatment of Alzheimer’s disease, targeting the glutamatergic pathway to improve cognition.

Alzheimer’s disease: helps to stabilize or modestly improve cognitive function and daily living activities in patients with mild to moderate disease.

Memantine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness that may affect balance. - Headache: mild to moderate pain in the head, sometimes accompanied by tension. - Constipation: reduced bowel movements or hard stools, potentially causing abdominal discomfort. - Fatigue: feeling unusually tired or weak, which can interfere with daily activities.

Serious or Rare Side Effects: - Seizures: convulsive episodes that may require emergency medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating possible anaphylaxis. - Hepatic dysfunction: elevated liver enzymes, jaundice, or other signs of liver injury.

When prescribing Memantine, clinicians should consider several safety precautions to minimize risks. - Renal function: assess kidney function before initiation and monitor periodically. - Hepatic function: evaluate liver status, especially in patients with pre‑existing liver disease. - Concomitant NMDA antagonists: avoid using with other NMDA‑blocking agents to prevent additive neuro‑inhibition. - History of seizures: use cautiously in patients with seizure disorders and monitor closely. - Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Memantine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine, ketamine): may increase neuro‑inhibitory effects. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): can reduce memantine plasma concentrations. - High‑dose zinc supplements: may interfere with absorption and reduce effectiveness.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation or dizziness. - Anticholinergic agents (e.g., diphenhydramine): may worsen cognitive side effects.